No abstract

Chronic nonbacterial prostatitis category III / chronic pelvic pain syndrome is detected in 90-95% of patients and depending on the disorders of proteolytic processes in the blood and prostate is subdivided into inflammatory (category IIIA) and non-inflammatory (category IIIB). The treatment of patients with chronic prostatitis must be complex, strictly differentiated and must provide for action on all etiological links and methods (drug and surgical) of treatment of CP. The paper determined the efficiency of entomological medication in chronic nonbacterial prostatitis and the contribution in preventing complications and improving the results of endoscopic transurethral treatment performed in this category of patients. It has been found that the administration of adenoprosine in combination with the standard complex physiotherapy of chronic nonbacterial prostatitis category IIIA and B (inflammatory and non-inflammatory) of the entomological preparation significantly increases the efficacy of the applied treatment, prevents or stops the evolution of chronic nonbacterial prostatitis consequences or intra- and postoperative complications in laser Ho: YAG transurethral endoscopic treatment, performed on the need of these categories of patients. Revolix laser prostate incision is a fast, harmless and promising procedure for, including, recurrent prostate sclerosis, and is used in the elimination of after bladder obstruction with satisfactory clinical results.

Background: The purpose of the study was to diagnose possible chronic nonbacterial prostatitis (CNP) and chronic pelvic pain syndrome (CPPS) among patients, as well as differentiate between the inflammatory (category IIIA) or non-inflammatory (category IIIB) types in selecting and optimizing differential drug treatment of this category of patients. Material and methods: The study was conducted on 43 patients diagnosed with CNP/CPPS. The control group included 10 healthy men. Both the production of nitric oxides (NO) by phagocytes, as well as prostate secretion and ejaculate were determined according to the procedure described by Metelyskaya B.A., which was modified by Gudumac V, et al. Results: There was a 39.0% (p <0. 05) decrease in NO production by induced NO-synthase (iNOS), determined in the blood of 11 patients (from the main group – 2) with CNP/CPPS and a 115% (p <0.05) increase was determined in 32 patients (from the main group 1) if compared to the same indices in the control group. The prostatic secretion and ejaculate showed a higher macrophage iNOS activity by 80% (p <0.05) and 75% (p <0.05) if compared to the same parameters from the control group. The iNOS activity in prostatic fluid and split-ejaculate fractions from the main group – 2 did not differ from that of the control group. Conclusions: The assessment of NO production, prostate secretion and ejaculate allows to somewhat establish the main diagnosis of CNP and category III types (A – inflammatory and B – non-inflammatory prostatitis), which will significantly contribute to the optimization and selection of an appropriate differential treatment based on the drug action mechanisms

No abstract

Chronic nonbacterial prostatitis category III/chronic pelvic pain syndrome is detected in 90-95% of patients and depending on the disorders of proteolytic processes in the blood and prostate is subdivided into inflammatory (category IIIA) and non-inflammatory (category IIIB). The treatment of patients with chronic prostatitis must be complex, strictly differentiated and must provide for action on all etiological links and methods of treatment of CP. The paper determined the efficiency of entomological medication in chronic nonbacterial prostatitis and the contribution in preventing compli- cations in this category of patients. It has been found that the administration of adenoprosine in combination with the standard complex physiotherapy of chronic nonbacterial prostatitis category IIIA and B (inflammatory and non-inflam- matory) of the entomological preparation significantly increases the efficacy of the applied treatment, prevents or stops the evolution of chronic nonbacterial prostatitis consequences.